These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 35050757)

  • 1. Comparison of Fast-Progression, Hyperprogressive Disease, and Early Deaths in Advanced Non-Small-Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or Chemotherapy.
    Ferrara R; Mezquita L; Texier M; Lahmar J; Audigier-Valette C; Tessonnier L; Mazieres J; Zalcman G; Brosseau S; Le Moulec S; Leroy L; Duchemann B; Lefebvre C; Veillon R; Westeel V; Koscielny S; Champiat S; Ferté C; Planchard D; Remon J; Boucher ME; Gazzah A; Adam J; Lo Russo G; Signorelli D; Garassino MC; Soria JC; Caramella C; Besse B
    JCO Precis Oncol; 2020 Nov; 4():829-840. PubMed ID: 35050757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The genomic characteristics of different progression patterns in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors.
    Li J; Xiang C; Wang Y; Zhou Y; Cao S; Ling X; Ye J; Zheng J; Shao L; Zhong H; Han Y
    Ann Transl Med; 2021 May; 9(9):779. PubMed ID: 34268392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy.
    Ferrara R; Mezquita L; Texier M; Lahmar J; Audigier-Valette C; Tessonnier L; Mazieres J; Zalcman G; Brosseau S; Le Moulec S; Leroy L; Duchemann B; Lefebvre C; Veillon R; Westeel V; Koscielny S; Champiat S; Ferté C; Planchard D; Remon J; Boucher ME; Gazzah A; Adam J; Bria E; Tortora G; Soria JC; Besse B; Caramella C
    JAMA Oncol; 2018 Nov; 4(11):1543-1552. PubMed ID: 30193240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Managing Hyperprogressive Disease in the Era of Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade: A Case Discussion and Review of the Literature.
    Grecea M; Marabelle A; Ammari S; Massard C; Champiat S
    Oncologist; 2020 May; 25(5):369-374. PubMed ID: 32091646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction model for hyperprogressive disease in non-small cell lung cancer treated with immune checkpoint inhibitors.
    Choi YJ; Kim T; Kim EY; Lee SH; Kwon DS; Chang YS
    Thorac Cancer; 2020 Oct; 11(10):2793-2803. PubMed ID: 32779394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperprogressive Disease (HPD) in Solid Tumours Receiving Immune Checkpoint Inhibitors in a Real-World Setting.
    Kanjanapan Y; Guduguntla G; Varikara AK; Szajer J; Yip D; Cockburn J; Fadia M
    Technol Cancer Res Treat; 2023; 22():15330338231209129. PubMed ID: 37885403
    [No Abstract]   [Full Text] [Related]  

  • 7. Hyperprogressive disease in patients with advanced cancer treated with immune checkpoint inhibitors.
    Şen GA; Öztaş NŞ; Değerli E; Guliyev M; Can G; Turna H; Özgüroğlu M
    Clin Transl Oncol; 2024 Dec; 26(12):3264-3271. PubMed ID: 39225958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria.
    Matos I; Martin-Liberal J; García-Ruiz A; Hierro C; Ochoa de Olza M; Viaplana C; Azaro A; Vieito M; Braña I; Mur G; Ros J; Mateos J; Villacampa G; Berché R; Oliveira M; Alsina M; Elez E; Oaknin A; Muñoz-Couselo E; Carles J; Felip E; Rodón J; Tabernero J; Dienstmann R; Perez-Lopez R; Garralda E
    Clin Cancer Res; 2020 Apr; 26(8):1846-1855. PubMed ID: 31757877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperprogressive Disease in Patients With Urothelial Carcinoma or Renal Cell Carcinoma Treated With PD-1/PD-L1 Inhibitors.
    Hwang I; Park I; Yoon SK; Lee JL
    Clin Genitourin Cancer; 2020 Apr; 18(2):e122-e133. PubMed ID: 31837940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma.
    Kim CG; Kim C; Yoon SE; Kim KH; Choi SJ; Kang B; Kim HR; Park SH; Shin EC; Kim YY; Kim DJ; Chung HC; Chon HJ; Choi HJ; Lim HY
    J Hepatol; 2021 Feb; 74(2):350-359. PubMed ID: 32810553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperprogressive Disease in Patients with Non-Small Cell Lung Cancer Treated with Checkpoint Inhibitors: The Role of
    Castello A; Rossi S; Mazziotti E; Toschi L; Lopci E
    J Nucl Med; 2020 Jun; 61(6):821-826. PubMed ID: 31862803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer.
    Sasaki A; Nakamura Y; Mishima S; Kawazoe A; Kuboki Y; Bando H; Kojima T; Doi T; Ohtsu A; Yoshino T; Kuwata T; Akimoto T; Shitara K
    Gastric Cancer; 2019 Jul; 22(4):793-802. PubMed ID: 30627987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1.
    Champiat S; Dercle L; Ammari S; Massard C; Hollebecque A; Postel-Vinay S; Chaput N; Eggermont A; Marabelle A; Soria JC; Ferté C
    Clin Cancer Res; 2017 Apr; 23(8):1920-1928. PubMed ID: 27827313
    [No Abstract]   [Full Text] [Related]  

  • 14. Hyperprogressive disease after treatment with pembrolizumab in lung adenocarcinoma: An autopsy case study.
    Tanaka Y; Matsubara O; Asada K; Muramatsu A; Suzuki M; Shirai T
    Respir Med Case Rep; 2019; 28():100885. PubMed ID: 31249779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive Nomogram for Hyperprogressive Disease During Anti-PD-1/PD-L1 Treatment in Patients with Advanced Non-Small Cell Lung Cancer.
    Wang X; Guo Z; Wu X; Chen D; Wang F; Yang L; Luo M; Wu S; Yang C; Huang L; Fu L
    Immunotargets Ther; 2023; 12():1-16. PubMed ID: 36632330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy.
    Kim SR; Chun SH; Kim JR; Kim SY; Seo JY; Jung CK; Gil BM; Kim JO; Ko YH; Woo IS; Shim BY; Hong SH; Kang JH
    BMC Cancer; 2021 Jan; 21(1):19. PubMed ID: 33402127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperprogressive Disease upon Immune Checkpoint Blockade: Focus on Non-small Cell Lung Cancer.
    Lo Russo G; Facchinetti F; Tiseo M; Garassino MC; Ferrara R
    Curr Oncol Rep; 2020 Apr; 22(5):41. PubMed ID: 32296957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunological Characteristics of Hyperprogressive Disease in Patients with Non-small Cell Lung Cancer Treated with Anti-PD-1/PD-L1 Abs.
    Kim KH; Hur JY; Koh J; Cho J; Ku BM; Koh JY; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ; Shin EC
    Immune Netw; 2020 Dec; 20(6):e48. PubMed ID: 33425433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities.
    Kanjanapan Y; Day D; Wang L; Al-Sawaihey H; Abbas E; Namini A; Siu LL; Hansen A; Razak AA; Spreafico A; Leighl N; Joshua AM; Butler MO; Hogg D; Chappell MA; Soultani L; Chow K; Boujos S; Bedard PL
    Cancer; 2019 Apr; 125(8):1341-1349. PubMed ID: 30768786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel patterns of progression upon immunotherapy in other thoracic malignancies and uncommon populations.
    Ferrara R; Signorelli D; Proto C; Prelaj A; Garassino MC; Lo Russo G
    Transl Lung Cancer Res; 2021 Jun; 10(6):2955-2969. PubMed ID: 34295690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.